{"organizations": [], "uuid": "adf16750674b1b2176306e728faff49326eb9c8a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-acorda-files-marketing-authorizati/brief-acorda-files-marketing-authorization-application-for-inbrija-idUSFWN1R80HB", "country": "US", "domain_rank": 408, "title": "BRIEF-Acorda Files Marketing Authorization Application For Inbrija", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-26T14:48:00.000+03:00", "replies_count": 0, "uuid": "adf16750674b1b2176306e728faff49326eb9c8a"}, "author": "", "url": "https://www.reuters.com/article/brief-acorda-files-marketing-authorizati/brief-acorda-files-marketing-authorization-application-for-inbrija-idUSFWN1R80HB", "ord_in_thread": 0, "title": "BRIEF-Acorda Files Marketing Authorization Application For Inbrija", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-acorda files marketing authorization applica", "sentiment": "negative"}, {"name": "acorda", "sentiment": "none"}, {"name": "acorda therapeutics inc", "sentiment": "none"}, {"name": "inbrija reuters", "sentiment": "none"}, {"name": "acorda therapeutics inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 26, 2018 / 11:51 AM / Updated 6 minutes ago BRIEF-Acorda Files Marketing Authorization Application For Inbrija Reuters Staff March 26 (Reuters) - Acorda Therapeutics Inc: * ACORDA FILES MARKETING AUTHORIZATION APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER) * ACORDA THERAPEUTICS INC - ‍ACORDA IS SEEKING MARKETING APPROVAL IN EUROPEAN UNION FOR INBRIJA​ * ACORDA THERAPEUTICS INC - ‍U.SFDA IS CURRENTLY REVIEWING A NEW DRUG APPLICATION FOR INBRIJA AND HAS SET AN ACTION DATE OF OCT 5, 2018 UNDER PDUFA​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-26T14:48:00.000+03:00", "crawled": "2018-03-26T15:03:47.105+03:00", "highlightTitle": ""}